Korean authorities continue to place pressure on the CDMO, after prosecutors raided the office of the national stock exchange regarding behaviour preceding the public listing of Samsung BioLogics.
Chi-Med in ‘prime position’ to take advantage of Chinese growth
from in-PharmaTechnologist.com
Lonza teams with hospital to produce CAR-T cells at point-of-care
from Outsourcing-Pharma.com
Mylan recalls sterile injection after particulate matter identified
from in-PharmaTechnologist.com
N-Side launches new clinical trial supply chain software
from Outsourcing-Pharma.com
Technology boosts access to biologics and insulin via oral delivery
Pipelines
Novasep and Sartorius combine forces on chromatography applications
Biosimilars
Biocon receives Form 483 due to risk of contamination
Emerging Markets
Sagent acquires US facility with an eye on future biosimilar products
Biosimilars
